[go: up one dir, main page]

MX2021008225A - Composiciones y metodos para tratamiento de crecimiento celular anormal. - Google Patents

Composiciones y metodos para tratamiento de crecimiento celular anormal.

Info

Publication number
MX2021008225A
MX2021008225A MX2021008225A MX2021008225A MX2021008225A MX 2021008225 A MX2021008225 A MX 2021008225A MX 2021008225 A MX2021008225 A MX 2021008225A MX 2021008225 A MX2021008225 A MX 2021008225A MX 2021008225 A MX2021008225 A MX 2021008225A
Authority
MX
Mexico
Prior art keywords
treatment
methods
cell growth
abnormal cell
compositions
Prior art date
Application number
MX2021008225A
Other languages
English (en)
Inventor
Mahesh Padval
Paul Okwabi Nkansah
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of MX2021008225A publication Critical patent/MX2021008225A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Esta invención se refiere a formas de dosificación oral y métodos que son útiles en el tratamiento de crecimiento celular anormal, tal como cáncer, en mamíferos, especialmente humanos.
MX2021008225A 2014-01-09 2016-07-08 Composiciones y metodos para tratamiento de crecimiento celular anormal. MX2021008225A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461925467P 2014-01-09 2014-01-09

Publications (1)

Publication Number Publication Date
MX2021008225A true MX2021008225A (es) 2021-08-11

Family

ID=52434976

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016009056A MX384259B (es) 2014-01-09 2015-01-09 Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2021008225A MX2021008225A (es) 2014-01-09 2016-07-08 Composiciones y metodos para tratamiento de crecimiento celular anormal.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016009056A MX384259B (es) 2014-01-09 2015-01-09 Composiciones y metodos para tratamiento de crecimiento celular anormal.

Country Status (15)

Country Link
US (3) US20150190346A1 (es)
EP (2) EP3091981B1 (es)
JP (5) JP6647204B2 (es)
KR (3) KR20240159639A (es)
CN (3) CN119868364A (es)
AU (4) AU2015204597B2 (es)
BR (1) BR112016016021B1 (es)
CA (1) CA2936283C (es)
DK (1) DK3091981T3 (es)
ES (1) ES2870562T3 (es)
IL (2) IL246667B (es)
MX (2) MX384259B (es)
NZ (2) NZ721934A (es)
SG (2) SG11201605588YA (es)
WO (1) WO2015106096A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3795157A4 (en) * 2018-05-15 2022-03-23 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING A SMALL MOLECULE EGFR INHIBITOR AND METHOD FOR PREPARING IT
JP2022547358A (ja) 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
EP4125896B1 (en) * 2020-03-27 2025-05-07 Pfizer Inc. Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
BRPI0413363A (pt) * 2003-08-04 2006-10-10 Pfizer Prod Inc formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
WO2008129380A1 (en) * 2007-04-18 2008-10-30 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth
JP5575768B2 (ja) * 2008-08-13 2014-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド 薬学的組成物およびその投与
WO2011112922A2 (en) * 2010-03-11 2011-09-15 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
WO2012027247A2 (en) * 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
KR20140011366A (ko) * 2011-03-08 2014-01-28 잘리커스 파마슈티컬즈 리미티드 고체 분산체 제형 및 그의 이용방법
EP2572731A1 (en) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions

Also Published As

Publication number Publication date
JP2023065568A (ja) 2023-05-12
CN119868364A (zh) 2025-04-25
WO2015106096A1 (en) 2015-07-16
AU2022256144B2 (en) 2025-04-03
DK3091981T3 (da) 2021-05-31
NZ721934A (en) 2022-04-29
ES2870562T3 (es) 2021-10-27
IL246667B (en) 2022-05-01
KR102444494B1 (ko) 2022-09-20
CN106102744A (zh) 2016-11-09
AU2020210153A1 (en) 2020-08-13
KR20160104725A (ko) 2016-09-05
AU2020210153B2 (en) 2022-07-21
JP2017502062A (ja) 2017-01-19
US20230104303A1 (en) 2023-04-06
IL292054A (en) 2022-06-01
EP3900726A1 (en) 2021-10-27
CA2936283A1 (en) 2015-07-16
JP6647204B2 (ja) 2020-02-14
AU2015204597B2 (en) 2020-04-30
AU2015204597A1 (en) 2016-07-21
JP2020007355A (ja) 2020-01-16
US20150190346A1 (en) 2015-07-09
SG10201805890QA (en) 2018-08-30
CN115708827A (zh) 2023-02-24
BR112016016021A2 (pt) 2017-09-19
KR20240159639A (ko) 2024-11-05
CA2936283C (en) 2023-02-28
JP2022001587A (ja) 2022-01-06
AU2025204843A1 (en) 2025-07-17
BR112016016021A8 (pt) 2018-04-17
EP3091981B1 (en) 2021-03-10
MX2016009056A (es) 2017-01-23
AU2022256144A1 (en) 2022-11-24
SG11201605588YA (en) 2016-08-30
MX384259B (es) 2025-03-14
IL246667A0 (en) 2016-08-31
EP3091981A1 (en) 2016-11-16
JP2025084892A (ja) 2025-06-03
NZ760233A (en) 2022-04-29
US20200038331A1 (en) 2020-02-06
BR112016016021B1 (pt) 2023-01-10
KR20220130251A (ko) 2022-09-26

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX389683B (es) Composiciones terapeuticas, combinaciones y metodos de uso
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
CL2017003404A1 (es) Compuestos antibacterianos
JOP20190194B1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
GT201700104A (es) Agonistas parciales del receptor de insulina
ECSP15048555A (es) Heterociclos bicíclicos como inhibidores de fgfr
MX2018006240A (es) Composiciones que comprenden cepas bacterianas.
MX2016010216A (es) Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY37018A (es) Inhibidores bicíclicos de pad4
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX381544B (es) Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
SG10201900598TA (en) Factor viii formulation
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.